Subscribe to RSS
DOI: 10.1055/a-2086-5446
Early Outcomes in Targeted Muscle Reinnervation for Traumatic Amputations
Funding Each author certifies that Stephen R. Denton has received research support funding from: Medical College of Wisconsin, Department of Orthopedic Surgery. Each author certifies that Stephen R. Denton's institution has received, during the study period, funding from: The National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant Number UL1TR001436. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Abstract
Background Traumatic amputees commonly experience residual limb pain (RLP) and phantom limb pain (PLP) which present major barriers to rehabilitation. An evolving treatment, targeted muscle reinnervation (TMR), shows promise in reducing these symptoms. While initial data are encouraging, existing studies are low power, and more research is needed to assess the long-term outcomes of TMR. We present the results of self-reported outcome surveys distributed to major-limb amputees more than 1 year post-TMR which were compared with similar data from a landmark randomized control trial for context.
Methods Data was obtained from 17 adult traumatic amputees who were more than 1 year post-TMR using a numerical rating scale and the Patient-Reported Outcomes Measurement Information System survey tool. Results were compared with a 2019 randomized control trial by Dumanian et al which assessed TMR versus standard care (SC) after major limb amputation and demonstrated improvement in pain scores 1 year post-TMR.
Results There was a statistically significant reduction in this cohort of TMR amputees' RLP worst pain scores relative to the comparison study's SC amputees (without TMR). In general, there was no significant difference in outcomes between TMR cohorts. However, PLP worst pain was significantly higher in this cohort relative to the comparison study's TMR group.
Conclusion These findings support the use of TMR for reducing RLP in traumatic amputees. Relative to a similar group treated without TMR in the comparison study, this cohort's RLP was significantly improved. Future studies should aim to recruit more amputees to allow for analysis of functional outcomes, especially in upper limb amputees.
Publication History
Received: 22 November 2022
Accepted: 20 March 2023
Accepted Manuscript online:
04 May 2023
Article published online:
13 June 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.
-
References
- 1 Ziegler-Graham K, MacKenzie EJ, Ephraim PL, Travison TG, Brookmeyer R. Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehabil 2008; 89 (03) 422-429
- 2 Huse E, Larbig W, Flor H, Birbaumer N. The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001; 90 (1-2): 47-55
- 3 Pierce Jr RO, Kernek CB, Ambrose II TA. The plight of the traumatic amputee. Orthopedics 1993; 16 (07) 793-797
- 4 Lu C, Sun X, Wang C, Wang Y, Peng J. Mechanisms and treatment of painful neuromas. Rev Neurosci 2018; 29 (05) 557-566
- 5 Flor H, Elbert T, Knecht S. et al. Phantom-limb pain as a perceptual correlate of cortical reorganization following arm amputation. Nature 1995; 375 (6531): 482-484
- 6 Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev 2016; 10 (10) CD006380
- 7 Wang X, Yi Y, Tang D. et al. Gabapentin as an Adjuvant Therapy For Prevention Of Acute Phantom-Limb Pain In Pediatric Patients Undergoing Amputation For Malignant Bone Tumors: A Prospective Double-Blind Randomized Controlled Trial. J Pain Symptom Manage 2018; 55 (03) 721-727
- 8 Cheesborough JE, Souza JM, Dumanian GA, Bueno Jr RA. Targeted muscle reinnervation in the initial management of traumatic upper extremity amputation injury. Hand (N Y) 2014; 9 (02) 253-257
- 9 Dumanian GA, Potter BK, Mioton LM. et al. Targeted muscle reinnervation treats neuroma and phantom pain in major limb amputees: a randomized clinical trial. Ann Surg 2019; 270 (02) 238-246
- 10 Mioton LM, Dumanian GA, Shah N. et al. Targeted muscle reinnervation improves residual limb pain, phantom limb pain, and limb function: a prospective study of 33 major limb amputees. Clin Orthop Relat Res 2020; 478 (09) 2161-2167
- 11 Souza JM, Cheesborough JE, Ko JH, Cho MS, Kuiken TA, Dumanian GA. Targeted muscle reinnervation: a novel approach to postamputation neuroma pain. Clin Orthop Relat Res 2014; 472 (10) 2984-2990
- 12 Valerio IL, Dumanian GA, Jordan SW. et al. Preemptive treatment of phantom and residual limb pain with targeted muscle reinnervation at the time of major limb amputation. J Am Coll Surg 2019; 228 (03) 217-226
- 13 Janes LE, Fracol ME, Dumanian GA, Ko JH. Targeted muscle reinnervation for the treatment of neuroma. Hand Clin 2021; 37 (03) 345-359
- 14 Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004; 8 (04) 283-291